DSCC1 antibody Polyclonal Antibodies Primary antibodies
- Known as:
- DSCC1 (anti-) Polyclonal Antibodies Primary antibodies
- Catalog number:
- orb100044
- Product Quantity:
- 100
- Category:
- -
- Supplier:
- Biorb
- Gene target:
- DSCC1 antibody Polyclonal Antibodies Primary antibodies
Related genes to: DSCC1 antibody Polyclonal Antibodies Primary antibodies
- Gene:
- DSCC1 NIH gene
- Name:
- DNA replication and sister chromatid cohesion 1
- Previous symbol:
- -
- Synonyms:
- DCC1, hDCC1, MGC5528
- Chromosome:
- 8q24.12
- Locus Type:
- gene with protein product
- Date approved:
- 2008-02-05
- Date modifiied:
- 2014-11-19
Related products to: DSCC1 antibody Polyclonal Antibodies Primary antibodies
Related articles to: DSCC1 antibody Polyclonal Antibodies Primary antibodies
- Natriuretic peptide receptor 1 (NPR1) plays a crucial role in maintaining the functionality of vascular endothelial cells. However, its role in regulating DNA replication and genome stability in endothelial cells remains unexplored. - Source: PubMed
Publication date: 2025/10/10
Zhang FengqingTang HongMao XiaochengXiong SiminWan YiqiYuan WeiLiu Hongfei - DSCC1, a key subunit of the alternative RFC complex, is essential for DNA replication and genome stability. While its role in cancers like breast cancer is documented, its function in LIHC remains largely unexplored. This study comprehensively examines DSCC1's involvement in LIHC. - Source: PubMed
Khan Abdul JamilMan ShadKhan Shahid Ullah - To explore novel biomarkers capable of predicting the prognosis of gastric cancer (GC) and investigate the mechanisms underlying the development of GC. - Source: PubMed
Publication date: 2025/04/19
Zhu XiulingCui ZhongyuanLi ShashaShe YingzhenWu Zhixian - Mammalian DNA double-strand breaks (DSBs) are repaired by homologous recombination (HR) and non-homologous end joining (NHEJ). HR occurs in the S/G2 phase, while NHEJ dominates in G1 phase. 53BP1 promotes NHEJ by recruiting RIF1 to DSBs in G1, but its inhibition during S/G2 remains unclear. Here, we identify DNA replication and sister chromatid cohesion 1 (DSCC1) as a key regulator that antagonizes 53BP1/RIF1 signaling in a cell-cycle-dependent manner. ATR-mediated phosphorylation of DSCC1 at Thr181 leads to its recruitment to DSB sites and promotes HR by facilitating DNA end resection. During S/G2, E2F1-induced DSCC1 expression is phosphorylated by cyclin-dependent kinase 2 (CDK2), enabling DSCC1 to interact with 53BP1 and restrain ataxia telangiectasia mutated (ATM)-mediated 53BP1 phosphorylation, consequently preventing RIF1 recruitment. Pathologically, DSCC1 is elevated in ovarian cancer, conferring poly (ADP-ribose) polymerase (PARP) inhibitor resistance. Thus, DSCC1 plays a crucial role in DSB repair pathway choice toward HR repair during S/G2 phase, providing a potential target to optimize PARP inhibitor therapy in BRCA1/2-proficient cancers. - Source: PubMed
Publication date: 2025/03/20
Tian JiaxinLi JiahengLiu FengqiWang CongSun BingheYan JinZhu BoQin YuFang ShentongZhang HaoxingChen Guo - As a component of the alternative replication factor C (RFC) complex, DSCC1 plays a significant role in cancer progression due to its aberrant expression. However, the potential function of DSCC1 in a pan-cancer context remains unclear. In this study, we conducted a comprehensive analysis of DSCC1's role in tumors by integrating multi-omics bioinformatics tools. First, we utilized various databases to compare the expression of DSCC1 between tumor and normal tissues, revealing a strong association between its dysregulated expression and clinical diagnosis, prognosis, and staging. Additionally, we investigated different mutation types of DSCC1 and their contributions to cancer progression, finding that DSCC1 expression is regulated by epigenetics and RNA modifications. Furthermore, we explored the correlation between DSCC1 and immune-infiltrating cells, as well as immunotherapeutic biomarkers, suggesting that its expression influences the tumor immune microenvironment. By employing single-cell and spatial transcriptome data through platforms such as SingleCellBase, CancerSEA, and CROST, we further uncovered the heterogeneity of DSCC1 across various cancer types. Finally, we validated the significant upregulation of DSCC1 mRNA in multiple tumor cell lines using q-RTPCR, and demonstrated through CCK8 assays that silencing DSCC1 expression effectively suppressed cell proliferation. Our findings establish a foundational understanding of DSCC1's potential as a biomarker for cancer diagnosis, prognosis, and immunotherapy. - Source: PubMed
Publication date: 2025/02/24
Cheng WeiLin Peng